Download the Investor Presentation & Receive Updates

Invest in a Pharmaceutical Cannabinoid Leader

Cardiol Therapeutics (TSX: CRDL) is a leader in the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer.

Exclusive Agreements

Innovative Technology

Agreements with Noramco and Dalton Pharma provide access to cannabinoid pharmaceuticals.

Nanotechnology research aims to enhance the delivery of cannabinoids for heart failure.

Cannabinoid Therapeutics

Experienced Team

Cannabinoid drug candidates for the treatment of heart failure and Glioblastoma Multiforme.

Team is experienced in the research and commercialization of novel therapeutics.

Sign Up to Learn More

Copyright © 2018 All Rights Reserved.